How patents, data exclusivity and SPCs interact to extend market exclusivity of medicines: the...
Patents usually confer 20-year exclusive rights on inventions. Data exclusivity laws confer, depending on the country, 5 to 10 years’ exclusive rights over safety...
Sharing know-how/trade secrets during a pandemic: We must be planning for it now
Medicines Law & Policy has recently proposed a provision for inclusion in the draft WHO pandemic instrument currently being discussed in Geneva (here and...
The EU proposed Covid waivers of certain TRIPS rules are mostly meaningless
Since October 2020, discussions have been ongoing at the World Trade Organization’s Trade-Related Aspects of Intellectual Property Rights (TRIPS) Council about a waiver of...
WTO Covid-19 TRIPS Decision: Some observations
This morning, 17 June at 5 AM the 12th World Trade Organization (WTO) Ministerial Conference (MC12) approved a package of decisions and declarations. The...
Pharmaceutical patents and data exclusivity in an age of AI-driven drug discovery and development
This is an excerpt from a longer report on AI, medicines development and the patent system.
Download the full report here (or by clicking...
What is the ‘know-how gap’ problem and how might it impact scaling up production...
This entire article is also available as a PDF by clicking here.
1. Introduction.
How relevant are concerns about intellectual property rights causing problems for...
Lessons for a pandemic preparedness treaty from previous successes and failures with treaty-based technology...
This post can also be downloaded as a PDF here.
1. Introduction
Scaling-up production of new vaccines to provide many billions of doses on a time-scale...
Proposed TRIPS waiver a hollow diplomatic compromise with little practical impact
In October of 2020, 9 months into the pandemic, fearing conflicts over intellectual property (IP) related to medical measures to fight the pandemic, India...
Never say never – Why the High Income Countries that opted-out from the Art....
To limit the ability of patent owners to charge excessive prices for patented medicines, countries can grant compulsory licences which permit others to produce...
Opmerkingen bij de notitie Dwanglicenties van B.J. Bruins, Minister voor Medische Zorg.
Op 15 juni 2018 stuurde Minister Bruins een notitie over dwanglicenties aan de Tweede Kamer. In deze briefing maken wij een aantal voorlopige opmerkingen...